Vaxart, Inc. (NASDAQ:VXRT), a biotechnology company specializing in the development of oral recombinant vaccines with a market capitalization of approximately $159 million, announced on Monday an ...

Scientists at the Institute for Systems Biology (ISB) have uncovered key insights into how T cells—the body's frontline ...

On Friday, February 7, a hearing took place in the Montana state legislature on a bill that would ban the use of mRNA ...

We recently compiled a list of the These 10 Firms Were Last Week’s Worst Performers. In this article, we are going to take a ...

To come up with last week’s worst performers, we considered only the stocks with at least $2 billion in market capitalization ...

Ratner, who heads the pediatric infectious disease unit at NYU Langone’s Hassenfeld Children’s Hospital, tracks the history ...

COVID-19 vaccination is linked to a transient decrease in hyperthyroidism risk but an increase in hypothyroidism risk over 12 ...

AIM Vaccine Co., Ltd., a leading PRC vaccine company, announced today that its independently developed mRNA RSV (respiratory syncytial virus) vaccine has recently been submitted for clinical trials to ...

The trial will evaluate the safety and effectiveness of a next-generation vaccine administered through a nasal spray or ...

I have heard many reasons residents haven’t accepted the vaccine: Vaccine burnout (too many vaccines being recommended like ...

Buying stocks at significantly reduced valuations can lead to some incredible returns later on. But that doesn't mean that ...

An image that is spreading widely online claims that Moderna had created its COVID-19 vaccine two years before the pandemic ...